EP0955045A1 — Drugs for improving ocular circulation disorders
Assigned to Senju Pharmaceutical Co Ltd · Expires 1999-11-10 · 27y expired
What this patent protects
An anti-ocular circulatory disturbance composition comprising 5-{1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl}-2-methylbenzenesulfonamide or its acid addition salt as an active ingredient. This composition can be used as a therapeutic and prophylactic drug for diseases cause…
USPTO Abstract
An anti-ocular circulatory disturbance composition comprising 5-{1-hydroxy-2-[2-(2-methoxyphenoxy)ethylamino]ethyl}-2-methylbenzenesulfonamide or its acid addition salt as an active ingredient. This composition can be used as a therapeutic and prophylactic drug for diseases caused by ocular circulatory disturbance, such as normal tension glaucoma, pigmentary retinal degeneration, macular regeneration, ischemic optic neuropathy, iridocyclitis, retinal artery occlusion, retinal vein occlusion, diabetic retinopathy, choroidal disease secondary to retinal lesions, and retina-choroidal disease, without a risk for adverse reactions. The composition shows excellent efficacy even by topical administration.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.